XENOTHERA, a French biotech company funded by the EIC, has publicly confirmed that its anti-Covid-19 treatment, named XAV-19, effectively treats several COVID-19 variants. The XAV-19 treatment is being tested in a clinical trial implemented in around 20 French hospitals.
With the appearance of new COVID-19 variants caused by the current virus' mutations, it is urgent to develop new treatments to address this pressing concern in the battle against the global pandemic. Here is where XENOTHERA is coming in with an important announcement: XAV-19, a treatment for patients with moderate symptoms of COVID-19, is efficient against different variants of the virus.
XENOTHERA is currently working in a clinical trial named POLYCOR to test XAV-19, with the Nantes University Hospital's endorsement, since September 2020. In this context, this innovative treatment is being tested in volunteers from around 20 different French hospitals. The goal is that, soon, the treatment will be available to an increasing number of patients, capitalising on the trial phase's visibility throughout French hospitals.
Furthermore, the XAV-19 treatment, implemented within POLYCOR, has received a label of "National Research Priority" from the French Health Ministry. Odile Duvaux, President of XENOTHERA, explained that the company had identified its antibodies' interest as a treatment against coronavirus infections for several years, which allowed them to have the first clinical batch of XAV-19 as of May 2020.
"The efficacy of XAV-19 against circulating variants was likely, given the polyclonal nature of our product. The advantage of XAV-19 against variants is now proven, unlike monoclonal antibodies. We are actively preparing our production capacities to be able to treat sick people," she concluded.
XENOTHERA has received a Phase 2 Grant from the European Innovation Council to develop a research project on polyclonal antibodies for the treatment of the COVID-19 infection, focusing on the XAV-19 solution.
DISCLAIMER: This information is provided in the interest of knowledge sharing and should not be interpreted as the official view of the European Commission, or any other organisation.